Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Hypertension. 2016 Aug 15;68(4):1004–1010. doi: 10.1161/HYPERTENSIONAHA.116.07681

Table 3.

Differences between study days

Parameters Intact Autonomic Blockade

ACh SNP ACh SNP
 MAP, mm Hg
Dose 1 109 ± 4.4 108 ± 4.8 81 ± 3.1 83 ± 3.4
Dose 2 107 ± 4.1 108 ± 4.5 81 ± 3.6 78 ± 4.1
Dose 3 108 ± 3.8 106 ± 4.2 78 ± 3.2 74 ± 3.4
P dose 0.922 0.253
P drug 0.819 0.532
P drug×dose 0.998 0.644
 FBF, ml/100 mL
Dose 1 4.2 ± 0.6 4.1 ± 0.5 7.9 ± 1.0 6.9 ± 0.8
Dose 2 6.0 ± 0.5 8.1 ± 0.4 10.7 ± 1.2 10.4 ± 1.3
Dose 3 7.2 ± 0.5 10.2 ± 0.7 13.2 ± 1.3 11.8 ± 1.0
P dose 0.001 0.000086
P drug 0.000 0.318
P drug×dose 0.016 0.873
 FVR, (MAP/FBF)
Dose 1 36.6 ± 7.4 33.7 ± 5.4 13.2 ± 1.9 13.8 ± 1.2
Dose 2 19.4 ± 1.5 13.5 ± 1.2 9.2 ± 1.2 8.6 ± 0.6
Dose 3 16.5 ± 1.6 10.9 ± 0.8 6.9 ± 0.8 7.0 ± 0.6
P dose 0.000 0.000
P drug 0.117 0.985
P drug×dose 0.959 0.872
 FVC, AU
Dose 1 3.8 ± 0.7 3.6 ± 0.5 9.3 ± 1.4 7.8 ± 0.7
Dose 2 5.6 ± 0.5 7.8 ± 0.5 13.1 ± 1.9 12.4 ± 1.0
Dose 3 6.6 ± 0.7 9.7 ± 0.8 16.9 ± 2.3 15.6 ± 1.6
P dose 0.000 0.000
P drug 0.001 0.346
P drug×dose 0.029 0.971

Values are expressed as mean ± S.E.M. The “p dose” reflects the effects of the different doses for both drugs, the “p drug” reflects the effects of each drug, the “p drug×dose” reflects the combined effect of both drug and the different doses.

HHS Vulnerability Disclosure